SmartNuclide Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series D

  • Investors
  • 24

SmartNuclide General Information

Description

Developer of radiopharmaceuticals designed for tumor imaging and therapy. The company utilizes radionuclide-protein conjugation and single-domain antibody platforms, providing recombinant human thyrotropin, pd-l1 diagnostic imaging agents, cd8+ t cells imaging agents, targeted radioligand therapies, radioisotope-targeted imaging agents, and radioactive therapeutic agents, enabling healthcare providers to access precise diagnostic and therapeutic options for oncology patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • A4-201/202, 206, Biopharmaceutical Industrial Park
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • A4-201/202, 206, Biopharmaceutical Industrial Park
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215000
  • China
+86 0512

SmartNuclide Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SmartNuclide Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series D) 14-Sep-2026 Completed Generating Revenue
6. Later Stage VC (Series C1) 09-Apr-2024 Completed Generating Revenue
5. Later Stage VC (Series C) 05-Jul-2021 Completed Generating Revenue
4. Early Stage VC (Series B) 09-Apr-2020 Completed Generating Revenue
3. Secondary Transaction - Private 12-Nov-2018 Completed Generating Revenue
2. Early Stage VC 01-Jan-2017 Completed Generating Revenue
1. Seed Round 21-Mar-2016 Completed Startup
To view SmartNuclide’s complete valuation and funding history, request access »

SmartNuclide Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
KGW Investment Growth/Expansion Minority
Star Capital Investment Management Growth/Expansion Minority
Beijing Ruihe Xinyi Investment Growth/Expansion Minority
Guangzhou Jiansu Private Equity Fund Management Growth/Expansion Minority
Healthib Capital PE/Buyout Minority
You’re viewing 5 of 24 investors. Get the full list »

SmartNuclide FAQs

  • When was SmartNuclide founded?

    SmartNuclide was founded in 2015.

  • Where is SmartNuclide headquartered?

    SmartNuclide is headquartered in Suzhou, China.

  • What industry is SmartNuclide in?

    SmartNuclide’s primary industry is Drug Discovery.

  • Is SmartNuclide a private or public company?

    SmartNuclide is a Private company.

  • What is SmartNuclide’s current revenue?

    The current revenue for SmartNuclide is .

  • How much funding has SmartNuclide raised over time?

    SmartNuclide has raised $43.6M.

  • Who are SmartNuclide’s investors?

    KGW Investment, Star Capital Investment Management, Beijing Ruihe Xinyi Investment, Guangzhou Jiansu Private Equity Fund Management, and Healthib Capital are 5 of 24 investors who have invested in SmartNuclide.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process